Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced a 1‑for‑10 reverse stock split that will take effect at 11:59 p.m. Eastern Time on December 15, 2025. The split will consolidate every ten shares into one, reducing the number of shares outstanding to roughly 959,533 and raising the per‑share price accordingly. Trading on a split‑adjusted basis will begin on December 16, 2025, and the company will continue to trade on Nasdaq under the symbol INBS with a new CUSIP number, 36151G709.
The reverse split follows a series of prior consolidations— a 1‑for‑20 split in February 2023 and a 1‑for‑12 split in January 2024— all aimed at meeting Nasdaq’s minimum bid‑price requirement and improving liquidity. While the split does not alter shareholders’ proportional ownership, it is intended to elevate the share price to a level that is more attractive to institutional investors and to avoid potential delisting risks. The board approved the split at the October 16, 2025 annual meeting, and the final ratio will be set within the authorized range.
Intelligent Bio Solutions has recently reported record revenue growth and margin expansion, with first‑quarter 2026 revenue reaching $1.11 million, a 32% sequential increase and 28% year‑over‑year growth, and gross profit margins rising to 46.6% from 39.68% in the prior year. President and CEO Harry Simeonidis highlighted that the company’s focus on consumable cartridge sales is driving recurring revenue and supporting the momentum. Despite these positive operational metrics, the reverse split is still viewed by some investors as a bearish signal, reflecting the company’s ongoing challenge of maintaining a higher share price.
The announcement was met with a negative market reaction, and analyst sentiment remains mixed. Some analysts maintain a buy stance, citing the company’s improving financials, while others express caution due to the repeated need for reverse splits and the potential perception of underlying weakness. The split is expected to improve liquidity and market perception, but it also underscores the company’s continued struggle to sustain a higher per‑share price without additional capital actions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.